Imjudo (tremelimumab-actl) is a cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) blocking antibody indicated: In combination with durvalumab for the treatment of adults with unresectable hepatocellular carcinoma (uHCC). In combination with durvalumab + platinum-based chemotherapy for adults with metastatic non-small cell lung cancer (NSCLC), without sensitizing EGFR mutations or ALK genomic aberrations. <a id="
Localización de Nuestra Oficina principal:
Dirección Física:
1441 F.D. Roosevelt Ave.
San Juan, P.R. 00936
Dirección Postal:
P.O. Box 363628
San Juan, P.R. 00936-3628
